Several KOLs have highlighted concerns over cost with Symbravo, since fixed-dose combination (FDC) drugs tend to be expensive.

The post AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine appeared first on Clinical Trials Arena.